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Summary 
The cytolethal-distending toxin (CDT), of Campylobacter jejuni was detectable, using 
an in vitro assay in most, but not all, 24 strains tested. The reason for the absence of 
toxin activity in these naturally-occurring CDT-negative C. jejuni strains was then 
investigated at the genetic level. CDT is encoded by three highly conserved genes, 
cdtA, B and C. In the CDT-negative strains, 2 types of mutation were identified. The 
CDT activities of C. jejuni strains possessing both types of mutation were 
successfully complemented with the functional genes of C. jejuni 11168.  The first 
type of mutation comprised a 667-bp deletion across cdtA and cdtB and considerable 
degeneration in the remainder of the cdt locus. Using a PCR technique to screen for 
this deletion, this mutation occurred in less than 3% of 147 human, veterinary and 
environmental strains tested. The second type of mutation involved at least 4 non-
synonymous nucleotide changes but only the substitution of proline with serine at 
CdtB-95 was considered important to CDT activity. This was confirmed by site-
directed mutagenesis. This type of mutation also occurred in less than 3% of strains as 
determined using a LightCycler biprobe assay.  
The detection of two CDT-negative clinical isolates questioned the role of CDT in 
some cases of human campylobacteriosis. To determine if anti-CDT antibodies are 
produced using human infection, a toxin neutralization assay was developed and 
validated using rabbit antisera. Pooled human sera from infected patients neutralized 
the toxin indicating expression and immunogenicity during infection. However, no 
neutralizing antibodies were detected in colonized chickens despite the expression of 
CDT in the avian gut as indicated by RT-PCR.  
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Introduction 
Campylobacter jejuni and C. coli are major causes of acute human bacterial enteritis 
in industrialised countries (35). These Campylobacter species asymptomatically 
colonize the intestinal tract of most mammals and birds (24) and one major route of 
human campylobacteriosis is assumed to be the consumption of contaminated poultry 
meat products (10). The pathogenic mechanisms by which campylobacters cause 
diarrhoea are as yet unknown, although motility, adhesion and invasion have been 
implicated (38). Several toxic activities have been reported but their roles in disease 
remain debatable (37). 
The best-characterised Campylobacter toxin is the cytolethal-distending toxin (CDT). 
CDT production has been described in several Gram-negative bacteria, including 
Escherichia coli (30, 33), Haemophilus ducreyi (7), Actinobacillus 
actinomycetemcomitans (21), Shigella dysenteriae (25, 26) and Helicobacter spp.(42).  
However, not all these species are implicated in enteric disease. In C. jejuni, CDT 
causes progressive cellular distension with eventual cell death (16). These 
morphological changes appear to be a consequence of alterations in the progression of 
the cell cycle, in particular cell cycle arrest in the G2/M phase (6, 8, 28, 41). 
CDT production is dependent on the expression of three tandem genes, cdtA, cdtB and 
cdtC (31). The CdtA, CdtB and CdtC proteins form a tripartite holotoxin complex 
required for CDT activity (18). Current evidence indicates that cdtB encodes the 
active/toxic component of the toxin while cdtA and cdtC are involved with binding to 
and internalisation into the host cell (18, 19). 
The role of CDT in human campylobacteriosis is unclear. Although, all C. jejuni 
strains tested to date appear to possess the cdt genes (11, 12, 31), the levels of toxin 
activities expressed are strain dependent, with 2 strains (~1.2 %) reported to produce 
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no detectable levels of CDT in vitro (2, 12). The explanation for such CDT-negative 
strains is currently unknown. In this study we have investigated the molecular basis of 
this using 8 C. jejuni CDT-negative strains isolated from human diarrhoeic stools 
(n=2), bacteremia (blood)(n=2), sheep (n=1), poultry processing plant (n=1) and a 
broiler (n=2). The results indicated that lack of the CDT phenotype was a 
consequence of either major deletions (51bp and 667bp) in or around cdtB or one or 
more point mutations within the cdtABC gene. Site directed mutagenesis and 
complementation were used to confirm these observations.  A PCR assay and a 
LightCycler BiProbe assay were developed to screen 123 randomly selected 
veterinary and human Campylobacter isolates for either the deletion or the 
predominant point mutation. The isolation of CDT-negative strains from cases of 
human campylobacteriosis questioned the role in disease of this potential virulence 
factor. Therefore, we developed an assay to detect specific anti-CDT neutralizing 
antibodies in the serum from infected individuals. The results of these studies 
indicated that circulating antibody responses, which neutralize CDT activity, are 
elicited during human infection but not during chicken colonization with C. jejuni.   
 
Materials and Methods 
 
Bacterial Strains and Growth Conditions: A panel of 24, human (n=10), veterinary 
(n=6) and environmental (n=8), C. jejuni strains were initially tested for CDT activity.  
In addition, 3 strains (81116, 11168, 81-176) of previously reported CDT activity and 
a cdtABC mutant of 81-176 (81-176cdt), kindly provided by Carol Pickett (41), were 
used as controls. The DNA from an additional 123 strains, isolated from humans, 
poultry, cattle and sheep, were tested in the molecular screening assays developed.  
73 
74 
75 
76 
77 
78 
79 
80 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
 4
Chemically competent E.coli TOPO10F’ (Invitrogen, Paisley, UK) and DH5αMCR 
(Invitrogen) strains were used for cloning and site directed mutagenesis studies, 
respectively. 
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C. jejuni  strains were grown for 24 h at 42 oC under microaerobic conditions (7.5 % 
O2, 7.5 % CO2, 85 % N2) on either Mueller-Hinton (M-H) or blood agar plates 
supplemented with 10% sheep blood, 50 μg/ml Actidione and selective antibiotics 
(Oxoid, Basingstoke, UK) (34). C. jejuni 81-176cdt was grown on media 
supplemented with 50 μg/ml kanamycin. E. coli was grown in Luria-Bertani medium 
(LB) under atmospheric conditions at 37 oC. Where necessary, LB medium was 
supplemented with 50 μg/ml ampicillin or 20 μg/ml chloramphenicol. The C. jejuni 
and E. coli strains were stored frozen at – 80 oC in 1 % (w/v) proteose peptone water 
containing 10 % (v/v) glycerol or in LB broth containing 50 % (v/v) glycerol 
respectively.  
 
In Vitro HeLa cell cytolethal distending toxin (CDT) assay: The assay used in this 
study was adapted from previously published CDT assays (14, 31). Cultured HeLa 
cells (ECACC, Porton Down, UK) were maintained in complete Eagle’s Minimal 
Essential Medium (EMEM) with 10 % (v/v) foetal bovine serum, 1 % (v/v) L-
glutamine, 1 % (v/v) non-essential amino acids and 0.5 % (v/v) gentamicin) at 37 oC 
in 5% CO2. For the assay, HeLa cell concentrations were adjusted to 2 x 104 cells ml-1 
and 150 μl of this suspension was added to each well of a flat-bottomed, tissue culture 
grade, 96-well plate. The cells were then cultured for 2-3 hours at 37 oC in 5% CO2, 
prior to the addition of bacterial lysates.  
Lysates were prepared from bacteria grown on M-H agar plates for 24 hours at 42 oC 
under microaerobic conditions and harvested into complete EMEM. The bacterial 
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suspensions were adjusted to OD550 1.6, sonicated on ice (1.5 min at 30 amp with 6-
sec pulses) (Vibra Cell, Sonics and Materials Inc, USA) and   cell debris removed by 
centrifugation (6000 g for 10 min at 4 oC). The lysates were sterilised by filtration 
using 0.22 μm filters (Minisart, Sartorius, Germany). Undiluted and 1 in 10 dilutions 
of the bacterial lysates were added to HeLa cells and two-fold dilutions performed 
across each plate, which were then incubated for 5 days at 37 oC in 5 % CO2.  The 
HeLa cell monolayers were then fixed in 10 % (v/v) formalin, stained with 2.3 % 
(w/v) crystal violet and examined by light microscopy. The toxin titres were 
expressed as the reciprocal of the highest dilution that caused 50 % of cells to become 
distended, and adjusted by dividing the OD550 of bacterial sonic lysates. Toxin titre for 
each strain was tested in at least three independent assays blind.  
 
CDT antibody neutralization assay: Hyperimmune rabbit antisera were produced 
against the whole organisms of C. jejuni strains 81116 (R12), EF (R43) and C37596 
(R42) as previously described (23). Serum from 10 chickens experimentally colonized 
with C. jejuni 81116, at 9 weeks post-challenge, were collected as previously 
described (3). Sera pooled from 6 human patients, taken 2-4 weeks after 
campylobacter isolation (pooled positive sera) and 6 human donors, with no recorded 
enteric infection (pooled negative sera), were used in the neutralization assay. The 
collection, storage and characterisation of these sera has been described previously (4, 
5).  
All sera used were initially treated at 56 oC for 2 hours to inactivate complement, 
before use in the in vitro HeLa cell CDT assays. Prior to the addition to the HeLa 
cells, 1/10 dilution of bacterial lysates were pre-incubated with R12 (1 in 50 dilution), 
R42 (1 in 30 dilution), R43 (1 in 30 dilution), pooled chicken sera (1 in 30 dilution) or 
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pooled human sera (1in 30 dilution), at 37 oC for 1 hour. Treated lysates were 
subsequently applied to the HeLa cells as described previously. 
148 
149 
150 
151 
152 
153 
154 
155 
156 
157 
158 
159 
160 
161 
162 
163 
164 
165 
166 
167 
168 
169 
170 
171 
 
Statistical Analyses: Experimental results from at least 3 independent assays were 
transformed to log (x+0.5) for analysis. Mean titres of each treatment were compared 
to controls by two-way analysis of variance and wherever treatment differences were 
p<0.05, indicated statistical significance.    
 
Western blotting: Whole-cell protein profiles of C. jejuni 11168 and 81-176 were 
prepared by separating on 12 % sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and electrotransferred to nitrocellulose membrane for 
western blotting as described previously (3). Membrane strips of each strain were 
incubated with the human and chicken sera (1/30 dilution) used for the CDT 
neutralization studies, and bound antibodies detected using species-specific anti-
immunoglobulin antisera conjugated to horse-radish peroxidase according to the 
manufacturers instructions (DakoCytomation Ltd, Cambridgeshire, UK and 
Amersham Biosciences UK Limited, Buckinghamshire, UK respectively). 
  
Polymerase chain reaction (PCR) assay for cdt genes: Chromosomal DNA was 
isolated from strains by the CTAB/NaCl method (1). Recombinant Taq DNA 
polymerase (Invitrogen) was used for all PCR reactions according to the 
manufacturer’s recommendations. Oligonucleotide primers used for PCR and 
sequencing reactions are given in Table 1 (Sigma Genosys, Haverhill, UK). PCR 
reactions were performed on a PE Applied Biosystems GeneAmp PCR 9700, with an 
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initial denaturation step of 95 oC for 5 min, followed by 25 cycles of 95 oC for 2 min, 
60 oC for 2 min and 72 oC for 1.5 min and a final extension step at 72 oC for 10 min.  
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Cloning and DNA sequence analysis of cdt genes: PCR reactions were repeated 
using Advantage cDNA Polymerase Mix , containing 3’- 5’ proof reading activity 
(BD Biosciences Clontech, Oxford, UK) according to the manufacturer’s instructions. 
PCR products were then cloned into pCR2.1-TOPO® (TOPO-TA cloning kit, 
Invitrogen) and transformed into chemically competent E. coli TOPO10F’ one shot® 
cells (Invitrogen) according to the manufacturer’s instructions. Plasmid DNA was 
isolated for analysis using a mini plasmid preparation kit (Qiagen Ltd, Crawley, UK) 
and the DNA inserts confirmed by restriction analysis. Inserts were sequenced using 
BigDye terminator cycle sequencing chemistry (Applied Biosystems, Warrington, 
UK) according to the manufacturer’s instructions. Sequenced products were separated 
on an ABI Prism 377 automated DNA sequencer (Applied Biosystems). DNA 
sequences were assembled and edited using SeqMan (DNAstar, Lasergene, Madison, 
USA) and ClustalV alignments to the published C. jejuni 81-176 cdtABC genes 
(GenBank accession number U51121) were done in MegAlign 5.00 (DNAstar, 
Lasergene, Madison, USA).  
 
Southern blot analysis: Genomic DNA (10 μg) was digested with the restriction 
endonuclease HindIII (Promega, Southampton, UK) overnight at 37 oC and used for 
Southern blot analysis using the CDP-star chemiluminescent detection reagent 
(Amersham Biosciences, Bucks UK) according to manufacturer’s instructions.  
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RNA extraction and reverse transcriptase PCR (RT-PCR): Total RNA was 
isolated from C. jejuni strains and chicken caecal contents using Tri reagent (Sigma 
Aldrich, Poole, UK) according to the manufacturer’s instructions. RNA was 
suspended in an appropriate amount of RNase free water and RNA concentrations 
estimated by spectrophotometry.  RT-PCR was carried out using the high fidelity 
ProSTAR HF single-tube RT-PCR system (Stratagene, Texas, USA), according to the 
manufacturer’s instructions. Since the cdt genes of C. jejuni strains are known to be 
expressed in a single mRNA transcript (14), RT-PCR primers DS15 and DS18 (Table 
1) were used to amplify the region between cdtA and cdtB.  RT-PCR was performed 
with an initial incubation step of 42 oC for 30 min, during which time cDNA was 
synthesised from the RNA template. The reverse transcriptase was inactivated and the 
cDNA denatured by incubation at 95 oC for 1 min, followed by an amplification 
reaction, comprising 40 cycles of 95 oC for 30 sec, 60 oC for 30 sec and 68 oC for 2 
min. RT-PCR products were visualised on 1.2 % (w/v) agarose gels.   
 
LightCycler BiProbe assay of cdtB polymorphism: For the LightCycler, PCR 
primers LC-T-F and LC-T-R (Table 1), were designed by alignment of the published 
sequence of the C. jejuni 11168 cdtB gene with the cdtB gene from C. jejuni strain EF, 
to amplify a 163 bp region encompassing codon 95 of cdtB. The polymorphism was 
detected by melting curve analysis of the probe LC-T-probe (Table 1) after PCR 
amplification. The probe was identical to the sequence of C. jejuni EF, containing a 
serine at codon 95 (tct). Amplification and probe hybridisation were performed in 20 
μl reactions using the LightCycler DNA Master SYBR Green I kit (Roche 
Diagnositics Ltd, Lewes, UK) in a LightCycler instrument (Roche Diagnostics Ltd). 
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Typically reaction mixtures comprised 10 – 15 pmol DNA, 2 pmol of LC-T-F, 5 pmol 
LC-T-R, 5 pmol LC-T-Probe and 3 mM MgCl2 in 1x LightCycler DNA master mix 
SYBR green mix. LightCycler PCR was performed for 50 cycles, with 15 s at 95 oC, 
5s at 55 oC and 10s at 74 oC with a transition rate of 20 oC/s. Fluorescence was 
measured at a wavelength of 540 nm (F1 channel) at the end of each amplification 
step to monitor the accumulation of PCR product. Melting curve analysis was 
performed immediately after amplification by heating the product to 94 oC (20oC/s), 
cooling to 40 oC for 10 s, and then heating to 85 oC (0.1oC/s). The final heating step 
was performed under continuous fluorescence measurement. DNA from C. jejuni EF 
and 11168 were included as positive controls and a no template control was included 
in each run.   
 
Complementation studies of CDT negative strains: Complementation of CDT-
negative strains was achieved by the introduction of the Campylobacter shuttle vector 
vector, pUOA18 (36), expressing a 2.4-kb region from C. jejuni 11168 containing the 
cdt genes (41). The region, included 206 bp of upstream and 106 bp of downstream 
sequence, was amplified with ClCdtABC-F and ClCdtABC-R (Table 1) and initially 
cloned into pCR2.1 TOPO. These primers included BamHI restriction enzyme sites at 
the 5’ ends of both primers. Following BamHI digestion and gel purification, the 
insert was ligated into dephosphorylated, BamHI digested pUOA18, to make the 
construct pCDT, and transformed to DH5αMCR (Invitrogen). The construct was 
isolated from E. coli and electroporated into C. jejuni EF and 99/68, using a method 
adapted from Wassenaar et al. (39). Colonies that appeared on 20 mg/ml 
chloramphenicol medium were tested for CDT activity in the in vitro CDT assay. 
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Site directed mutagenesis of cdtB-95. Pro-95 of CdtB was changed to Ser-95 using 
the QuikChange® XL Site-Directed Mutagenesis Kit (Stratagene), according to the 
manufacturer’s instructions. Mutagenic primers (Table 1) were used to generate 
pCdtBP95S and mutants identified by HaeIII restriction digestion of the cdtABC genes 
and sequencing of the entire insert.  
 
Chick colonization model: A quantitative chick colonization model was used as 
previously described (40). Briefly, groups of 10 specific pathogen-free, 1-day old 
chickens (Charles River SPAFAS Inc., Hanover, Germany), housed in isolators, were 
dosed by oral gavage with C. jejuni 81-176, 81-176 cdtABC-, C289/6. Doses, 
administered in 100 μl 0.1 M PBS , ranged from 102 - 109 colony forming units 
(c.f.u). Doses were prepared by harvesting bacteria, grown overnight on 10 % blood 
agar plates at 42 oC, into sterile 0.1 M PBS. At five days post challenge, colonization 
levels were determined by plating of dilutions of caecal contents. Colonization levels 
were determined as c.f.u. per gram of caecal contents for individual birds. All animal 
experiments were performed in accordance with the local ethics committee and UK 
home office licence guidelines.        
 
Nucleotide sequence accession numbers: The cdt gene sequences have been 
submitted to the GenBank database under the following accession numbers: C. jejuni 
C37596 - AY442300, C. jejuni C35926 - AY442302, C. jejuni C37533 - AY442301 
and C. jejuni EF – AY445094. 
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Identification and characterisation of CDT-negative C. jejuni strains: A panel of 
24 selected C. jejuni strains were tested for CDT activity. A range of CDT-activities, 
from titres of <50 (n=13), 50-150 (n=4), 150-300 (n=2) and >300 (n=1), were 
observed but there was no obvious correlation with strain source (data not shown). Of 
the 24 strains tested 4  (C37596, C35926, C37533 and EF) had no detectable CDT 
activity. Two of these CDT-negative strains, C37596 and C35926, were isolated from 
the blood of independent campylobacteriosis patients (within the UK in 2000) with 
underlying medical problems, as discussed later.  C. jejuni strain C37533 was isolated 
from the faeces of the same patient as isolate C37596. None of these strains were 
serotypable. The remaining CDT-negative strain (EF) was isolated from a chicken 
carcass in the chilling area of a poultry-processing plant. 
The presence of cdtABC genes in all 24 strains was determined by PCR. In 21 of the 
24 strains, the expected PCR amplicon size of 2143 bp, generated with primers CdtF 
and CdtR, was observed (Fig. 1). However, in strains C37596, C35926 and C37533, 
which were CDT-negative, a smaller product of 1400 bp was detected. The PCR 
products of all 4 CDT-negative strains were cloned and sequenced. ClustalV 
alignment, to the published cdtABC sequence of C. jejuni 81-176 (Accession number 
U51121), revealed a 667-bp deletion between cdtA and cdtB and a separate 51-bp 
deletion within the cdtB genes of strains C37596, C35926 and C37533, consistent 
with the reduced PCR amplicon size observed by PCR (Fig. 2). The remainder of the 
sequences from these three strains had only 51% identity, which was due to additional 
indels (insertions-deletions) and substitutions throughout the remaining cdtABC gene 
sequence.  
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We next determined, by Southern blot hybridisation, whether the 667 bp deleted 
region between cdtA and cdtB was the result of recombination with another part of the 
genome or whether it was completely lost from the genome. Using primers specific 
for this region (C7del), a PCR product was generated from strain 11168, and used to 
probe HindIII-digested genomic DNA of strains C37596, C35926 and C37533. The 
results confirmed the absence of the region between cdtA and cdtB in the genomic 
DNA of these strains (data not shown).  
To determine the prevalence of the 667 bp deletion in C. jejuni isolates, the DNA of 
an additional 123 randomly selected clinical and veterinary strains were screened by 
PCR using the primers Cdt-F and Cdt-R. All but one strain, 99/68, produced a PCR 
product of 2.14 kb. Strain 99/68, which was isolated from a broiler, produced an 
amplicon of only 1400 bp indicative of a deletion. Cloning and sequencing of this 
amplicon revealed 96% sequence identity with the cdt genes of C37596, C35926 and 
C37533 previously identified as having the same deletions (data not shown).  This 
result indicates that significant deletions in the cdt genes occur in 2.7 % (4 of 147 
isolates tested) of C. jejuni strains, but when such deletions in the cdt gene locus are 
present, they were found between cdtA and cdtB.  
Interestingly the sequence of the cdt genes from the CDT-negative strain, EF, 
identified 18-nucleotide substitutions compared to previously published sequences of 
C. jejuni cdtABC (11168 & 81-176). Sequence analysis indicated that all three reading 
frames were open in C. jejuni EF. Of the 18 nucleotide substitutions, only four were 
identified as non-synonymous: involving an alanine to a valine at codon 88 in CdtA; a 
proline to serine and methionine to threonine at codons 95 and 120 of CdtB 
respectively (Fig. 3); and an isoleucine to asparagine at codon 167 of CdtC. In order 
to determine if the lack of CDT activity in strain EF was due to a loss of gene 
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expression rather than the substitutions, RT-PCR analysis was undertaken. Total RNA 
extracted from C. jejuni EF was used as a template and RT-PCR was carried out, 
using the DS15 and DS18 primers (Table 1). A mRNA transcript was detected from 
both C. jejuni EF and 11168 (Fig. 4A), indicating that gene expression occurred and 
that the lack of toxicity was most likely caused by the production of inactive toxin, 
probably as a consequence of one or more of the amino acid substitutions. 
Alignment of the CdtB amino acid sequence from other CDT-producing bacteria, 
revealed Pro-95 to be a highly conserved residue (Fig. 3), suggesting that this residue 
is important for the function of the protein. In order to determine the frequency of the 
mutation at this residue, melting curve analysis using a LightCycler assay with a 
probe designed to match the EF Ser-95 mutation was developed and performed on the 
original 24 strains and the additional 123 strains (Fig. 5). The assay identified two 
strains (99/373 and S58 from a human and a sheep respectively) in addition to EF, 
which gave a melting temperature of 60 oC indicating the presence of the Ser-95 
mutation. A third strain (99/12), also from a broiler, was identified, which had a lower 
melting temperature of 48 oC, suggesting that more than one mutation was present 
within the region probed. These observations were further confirmed by sequencing 
of the cdtABC genes. Strain 99/373 and S58 were identical at the amino acid level to 
C. jejuni EF, except that S58 did not have the substitution in CdtC at codon 167 of an 
isoleucine to asparagine. In contrast, the sequence of 99/12 revealed several additional 
amino acid substitutions to those found in C. jejuni EF; 8 of these occurred in CdtB 
and 6 in CdtC. In addition to these substitutions, 4 nucleotide insertions and 1 deletion 
were also identified. Overall the frequency of the Pro-95-Ser mutation as detected by 
the LightCycler BiProbe assay, was 2.29 % (3 of 147 strains tested). The absence of 
CDT activity in strains 99/373, S58 and 99/12 was confirmed using the in vitro HeLa 
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cell CDT assay (data not shown). By RT-PCR the cdt genes were transcribed in 
strains 99/373, S58 and 99/12 (Fig. 4B), providing supporting evidence that once 
again suggesting that these mutations were associated with the lack of CDT activity. 
343 
344 
345 
346 
347 
348 
349 
350 
351 
352 
353 
354 
355 
356 
357 
358 
359 
360 
361 
362 
363 
364 
365 
366 
367 
 
Complementation and site directed mutagenesis: To verify whether CDT negative 
strains could produce active CDT, the complementation vector (pCDT), containing 
functional cdt genes of C. jejuni 11168 was introduced into C. jejuni EF and 99/68. 
All transformants tested produced active CDT in the in vitro CDT assays, with levels 
comparable to C. jejuni 11168 (Fig. 6).  
To ascertain whether the proline residue at CdtB-95 was essential for CDT activity, 
site directed mutagenesis was used to mutate proline to serine at this residue in the 
complementation vector pCdt to generate pCdtBP95S. C. jejuni EF and 99/68 were 
complemented with pCdtBP95S and transformants tested for CDT activity.  The single 
mutation at CdtB-95 to serine resulted in a 98.4 % (p =0.0004) and 97.3 % (p<0.0001) 
reduction in CDT titre, for EF and 99/68 respectively (Fig. 6). These results indicated 
the residue at CdtB-95 is critical for the toxicity of CDT in C. jejuni.   
 
The expression and immunogenicity of CDT during colonization: As yet there are 
no suitable in vivo models of campylobacteriosis (22), however the one day-old 
chicken is an excellent model of colonization. Challenge of one-day-old chicks with 
the CDT negative mutant of 81-176 gave the same level of colonization, up to 109 cfu 
per gram of cecal contents, as the parent strain (data not shown) suggesting that the 
absence of CDT expression does not affect colonization potential.  
Despite this high level of colonization no clinical signs of disease were discernable in 
chicks challenged with either the mutant or the wild type strain.  These differences in 
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outcome of colonization in the chicken and human are well recognised but 
unexplained (22).  To determine whether the cdt genes were expressed during chicken 
colonization, the caecal contents of chicks challenged for up to 10 days with CDT-
positive C. jejuni strain C289/6 was investigated by RT-PCR. The results indicated 
that CDT is expressed during colonization of the avian gut (Fig. 7).  
As determining the CDT expression in humans by a similar approach was not 
feasible, an alternative approach was sought. For other bacteria, the development of 
host circulating anti-toxin antibody responses has provided indicators of both in vivo 
expression and the virulence potential of putative toxins (9, 13). Therefore an assay to 
detect specific anti-CDT antibodies was developed. In this assay sera, from 
experimentally colonized chickens, hyperimmunised rabbits and patients with 
campylobacteriosis, were tested for their capacities to neutralize the in vitro CDT 
activity from 3 CDT-positive C. jejuni strains 81116, 81-176 and 11168 which had 
CDT titres of 23.6 (± 0.8), 16.2 (± 3.7), 28.6 (± 4.8) respectively. When lysates from 
these strains were pre-treated with rabbit anti-C. jejuni 81116 antisera (R12) the CDT 
activity was completely or largely neutralized (100%, 100% and 79% respectively) 
(Fig. 8), where as no neutralisation was observed with sera from the preimmunised 
rabbits. Thus indicating that the CDT expressed during in vitro culture is antigenic in 
immunized rabbits. To confirm the specificity of this neutralizing activity, rabbit 
antisera directed against two of the CDT-negative strains, C37596 (R42) and EF 
(R43), were also tested in the neutralization assay. As expected R42 did not neutralize 
the CDT activity of any of the strains tested, which is consistent with the presence of 
the large deletions and substantial degeneration of the cdt locus in this strain. In 
contrast R43 only partly neutralized (71%, 54% and 46%) the CDT activities of 
strains 81116, 81-176 and 11168 respectively (Fig. 8), probably reflecting changes in 
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antigenic structure of CDT in strain EF as a consequence of the amino acid sequence 
variation. 
The neutralization assay was further used to determine the presence of anti-CDT 
neutralizing antibodies in pooled sera from patients convalescing from 
campylobacteriosis. Previous studies, using ELISA and western blotting (4), 
demonstrated the presence and specificity of anti-campylobacter antibodies in the sera 
from each individual patient. Complete (100 %) neutralization of the CDT activity 
was observed in all strains (Fig. 8). This level of neutralization was significantly 
higher (p= 0.001) than the level of neutralization obtained with pooled human sera 
from blood donors with no history of enteric disease and no demonstrable anti-
campylobacter antibodies as detected by ELISA and western blotting (4), indicating 
that CDT is both expressed during human infection and induces antibody responses.   
Finally we investigated the presence of neutralizing anti-CDT antibodies in the pooled 
sera of chickens experimentally colonized with C. jejuni 81116.  The development of 
humoral responses directed against the antigens of this strain during colonization has 
been reported previously (3) and in two other strains by western blot (Fig. 9). 
Interestingly, in contrast to antibodies from colonized humans and immunised rabbits, 
these chicken antibodies demonstrated no detectable CDT neutralizing activity (Fig. 
8.) against either the homologous strain or the two heterologous strains. 
  
Discussion 
The lack of a suitable small animal model of campylobacteriosis continues to be a 
major limitation to our understanding of the bacterial pathogenic mechanisms 
involved in campylobacteriosis. Thus potential C. jejuni virulence factors have been 
largely defined on the basis of in vitro properties. Although, many toxin activities 
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have been observed in C. jejuni strains in vitro, to date only CDT has been sufficiently 
characterised to suggest that this is a true virulence factor with a role in enteric 
campylobacteriosis. Our observations confirmed previous reports (12, 31) that the 
majority of C. jejuni strains express detectable CDT activity. However, clearly the 
level of CDT activity expressed varied between strains and, moreover, some strains 
expressed no detectable activity.   
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Although CDT-negative C. jejuni strains have been described previously (11, 12, 31), 
the frequency, molecular basis and potential consequences of this negative phenotype 
have not been fully investigated. From our studies two distinct types of naturally 
occurring mutation have been identified in the cdt locus of CDT-negative strains. The 
deletion mutation, detected in isolates from 2 unrelated patients and a broiler, 
involved a 667-bp deleted region between cdtA and cdtB, and a separate 51 bp 
deletion further downstream in cdtB, as well as several point mutations throughout the 
remaining cdt genes. Southern blot analysis indicated that these observations were the 
consequence of a genomic deletion rather than a transition. It, therefore, seems likely 
that the major deletion occurred first followed over time by the subsequent 
degeneration of the residual surrounding, now redundant, genetic material.  
The recovery of such mutants from albeit immunocompromised patients with clinical 
symptoms calls into question the role of active CDT in the pathogenesis of 
campylobacteriosis. That CDT is not required for effective colonization of the avian 
intestine was supported by results from this study using the experimental challenge of 
one-day-old chicks with a defined cdt mutant and of the mammalian intestine by 
previously published work using a cdtB mutant (32). However, without a suitable 
animal model, the role of CDT in disease is more difficult to determine. Two out of 
the three clinical infections with CDT-negative strains, were in patients with 
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underlying problems, of cirrhosis and/or neutropenia, which could potentially induce 
an immune compromised status and thus influence the outcome of that infection. 
Interestingly, both patients developed campylobacter bacteraemia.  However, in one 
of these patients, from whom strain C37596 was isolated, an earlier faecal isolate 
(C37533) was also recovered during a period of acute enteritis and had the same 
mutation as the blood isolate. The isolation of CDT negative faecal strains (C37533, 
99/373) from patients with enteric disease, indicates that CDT expression is not 
essential for the production of enteric disease in humans. Mechanisms other than CDT 
expression may be involved in the outcome of campylobacteriosis. Similar large 
deletions have been described in the toxin genes of other bacteria without obvious 
consequences for disease outcome. For example large deletions (1.18 kb and 5.08 kb) 
have been reported in the vacuolating cytotoxin (vacA) of Helicobacter pylori (15) 
and yet these isolates were still associated with gastritis and peptic ulceration. 
The second type of naturally occurring mutation identified in  CDT-negative strains (4 
out of 147 strains tested) from various sources (poultry processing plant, broiler, 
sheep and a human), were point mutations resulting in at least 3 amino acid 
substitutions. As RT-PCR demonstrated that the cdt genes of these strains were 
transcribed, we hypothesised that these mutations resulted in the loss of CDT activity. 
This hypothesis was further supported by complementation and site directed 
mutagenesis studies in which the CDT activity was restored by cdt genes from a 
CDT-positive strain. 
Because CDT is a tripartite protein, in which the CdtA and C subunits are required for 
the delivery of the CdtB subunit containing the enzymatically active site associated 
with toxin activity (18), non-synomonous point mutations in these genes may have 
different effects on phenotype. The comparisons of the sequences within this group of 
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strains suggest that the minimal set of mutations required to induce naturally 
occurring CDT-negativity were represented in strain EF. In this strain a mutation 
resulting in the replacement of alanine with valine, at codon 88 was detected in CdtA.  
This change was also conserved in the other two CDT-negative strains within this 
group. As both amino acids are aliphatic, hydrophobic and have non-polar side chains, 
this transition is unlikely to substantially affect the structure or folding of the 
polypeptide chain. Moreover, alignment of CdtA amino acid sequences from 
Haemophilus and Actinobacillus species with that from strain EF, also showed a 
valine at this position (data not shown) and as both these bacterial species produce 
active CDT, it appears that this polymorphism within the CdtA subunit has little 
consequence for the activity of this toxin.  The mutation at codon 167 of CdtC 
resulted in the replacement of isoleucine with asparagine and was found in an 
additional C. jejuni strain 99/373, a human isolate. This results in a change from a 
non-polar hydrophobic residue to a hydrophilic polar residue. Alignment of the CdtC 
amino acid sequence from Helicobacter hepaticus with that from C. jejuni 11168 
shows that the two sequences are identical at this position.  This substitution may 
therefore have possible a role in the lack of CDT activity in C. jejuni EF.  
Moreover, there were two potentially important non-synonomous changes in cdtB in 
this group of CDT-negative strains.  All demonstrated a substitution of methionine by 
threonine at CdtB-120. Although this could potentially influence the 3-dimensional 
structure of CdtB, alignment of the amino acid sequences from other bacterial species 
shows considerable variability at this position (Fig. 3.), suggesting that this mutation 
in CdtB would have little, if any, consequence for CDT activity. In contrast, the 
substitution of proline with serine at CdtB-95, appeared more important. Proline at 
Cdt-95 appears a highly conserved residue (Fig. 3.) and its role in CDT activity has 
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now been confirmed using site directed mutagenesis.  Interestingly, CDT is known to 
have similarities with diphosphodiesterases, the active sites of which have been 
identified (17, 20).  However, neither CdtB-95 nor any other of the mutations 
identified in C. jejuni EF fell into the conserved or functionally important residues 
predicted for such enzymes.  Although, CdtB-95 is clearly essential for CDT activity, 
whether, any of the observed or, or as yet unidentified, mutations within the cdt locus 
could explain the observed variability in levels of CDT activity detectable in vitro is 
unknown.   
For toxins expressed by related organisms, such as the VacA of Helicobacter pylori 
(9, 29), the immunogenicity of the toxin during infection, as determined by western 
blotting, is considered both evidence of in vivo expression and importance as a marker 
of pathogenicity. Unfortunately, western blotting of C. jejuni cell preparations using 
anti-CDT antibodies from human campylobacteriosis patient sera proved 
unsuccessful. Therefore, we developed a CDT neutralization assay to detect serum 
anti-CDT antibodies. This assay was validated using serum from a rabbit 
hyperimmunised with the whole cells of CDT-expressing C. jejuni strain 81116. This 
antiserum completely neutralized the CDT activity of this strain. The specificity of 
these neutralizing antibodies was then demonstrated using rabbit antiserum directed 
against strain C37596 that contained the large deletions in the cdt locus. This 
antiserum failed to neutralize the toxin activity of C. jejuni 81116, 11168 and 81-176. 
In contrast antiserum directed against strain EF, containing the point mutations partly 
neutralized this activity. Comparison of the neutralizing capacity of the anti C. jejuni 
81116 antisera against several strains suggests that the observed variation may be due 
to a quantitative rather than a qualitative variation in toxin titre (due to coding region 
differences), which may be under some regulatory control.  
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This CDT neutralization assay was then used to investigate the presence of 
neutralizing antibodies in the sera of patients recovering from campylobacteriosis. 
Because of the limited availability of such human sera, and the large volumes of sera 
required for such studies, a pool of 6 patients’ sera was used and compared with a 
pool of 6 sera from donors with no laboratory confirmed history of enteric disease. 
Previous studies using ELISA and western blotting had already demonstrated the 
presence of specific anti-campylobacter antibodies in the sera from the individual 
patients and the absence of these antibodies in the sera from the individual control 
donors (4, 5).  The results clearly demonstrated the complete neutralization of CDT 
activity by the pooled sera from the campylobacteriosis patients. In contrast, the level 
of neutralization by the pooled sera from the control donors was significantly lower 
(p=0.001). These results suggest that CDT is expressed by C. jejuni during human 
enteric infection and is antigenic, and that antibodies directed against this antigen can 
neutralize the toxin activity.  
Finally, the neutralization assay was also used to investigate CDT immunogenicity 
during chicken colonization. This absence of detectable neutralizing antibodies, 
despite a substantial antibody response in colonized chickens (Fig. 9) (3) and the 
demonstrable expression of CDT in the avian gut, was surprising but suggests that 
CDT is not antigenic in chickens. The reason for this is currently under investigation 
but may reflect host-specific differences in immune responsiveness particularly as the 
colonization model uses young chicks. It is possible that non-neutralizing antibodies 
are induced. However, it is well recognised that colonization in chickens, unlike 
humans, is asymptomatic.  Thus the relationship between the lack of detectable 
immunogenicity of CDT in the chicken and the absence of a disease outcome of 
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colonization may be a valuable future approach to the investigation of host-specific 
differences in campylobacter infection.   
In summary CDT remains the only clearly identified toxin in the genome sequence of 
C. jejuni (27). Nevertheless, the recovery, albeit rarely, of naturally occurring CDT-
negative C. jejuni strains raises questions about the role of this toxin in 
Campylobacter biology.  However, infected patients, with disease symptoms, elicited 
circulating and neutralizing antibodies directed against this toxin during infection. 
Moreover, the absence of similar antibodies in colonized, asymptomatic chickens 
suggests that the role of this toxin in disease requires considerable further 
investigation. 
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Table 1 – Primers and probes used in study 
 
 Primer or 
Probe 
5’- 3’  oligonucleotide
sequence
Amplicon
size
Comments 
Cdt-F gcggaaaattataatgaaattta
Cdt-R gcaaggggctattccaaagc
2143bp Amplification of  cdtABC genes *
C7-F-Del cggatgagccttgcaaattc
C7-R-Del gatcaatcctcgctttaaaga
700 bp
Amplification of region between
cdtA and  cdtB 
DS18 ‡ ccttgtgatggcaagcaatc
DS15 ‡ acactccatttgctttctg
300 bp
Amplification of region between
cdtA and  cdtB ‡ 
LC-T-F  † gatatcttaatgatacaagaagc
LC-T-R  † ctacatcaacgcgagaataa
162 bp
Amplification of region
encompassing  CdtB  codon 95
LC-T-Probe  † 
cy5 -  taaaaaccctatcagaccttga
- biotin
Hybridises to  CdtB  codon 95
ClCdtABC-F ccaaagggtctttccaagag
ClCdtABC-R aaattattatagagcaaggtaaattac
2493 bp Amplification of  cdtA ,  cdtB and
cdtC including promoter  regionc
SDMT1291- 
F 
ggaatttaggaactctttcaaggtctga
tagggtttttatttattattctcg
SDMT1291- 
R 
cgagaataataaataaaaaccctatca
gaccttgaaagagttcctaaattcc
Site directed  mutagenesis
primers 
*  cdt gene primers were designed to amplify a product from 41 nucleotides upstream of  cdtA , including all
of  cdtB and the first 486 nucleotides of cdtC.
† 
  LightCycler Primers and Probe were synthesised by MWG-Biotech UK Ltd (UK).
‡  RT-PCR primers used were taken from Hickey at al. (14).
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FIG. 1. Amplified products of cdtA, B, and C of selected strains, with known in vitro 
CDT activity, using primers cdt-F and cdt-R.  
 
FIG. 2. Schematic diagram of the cdtABC of C. jejuni 81-176 illustrating the locations 
of the 667 and 50 bp deletions in strains C37596, C37533 and C35926. Arrows 
indicate direction of transcription  
 
FIG. 3. Alignment of the CdtB amino acid sequences of C. jejuni strains EF, 11168 
and other bacterial species. Shaded areas highlight amino acids identical to C. jejuni 
11168. Accession numbers are as follows: C. jejuni EF - AY445094, C. jejuni 11168 
CdtB - CAB72564, C. upsaliensis CdtB - AAF98364, A. actinmyetemcomitians CdtB 
- AAC70898. H. ducreyi CdtB - AAB57726, H. hepaticus CdtB - AAF19158 and E. 
coli CdtB -2010282B. Asterisks indicate point mutations found in C. jejuni EF. The 
amino acids are numbered continuously on the left. 
 
FIG. 4. RT-PCR to detect the expression of CDT in C. jejuni EF and 11168, using 
primers DS15 and DS18 to amplify a 450 bp region overlapping cdtA and cdtB (Panel 
A) and strains, 99/373, S58 and 99/12 (Panel B). Lanes A – reverse transcribed RNA 
sample, lanes B- RT negative controls; lanes C, DNA controls. Lanes containing a 1 
kb ladder were included (MW).  
 
FIG. 5. Melting curve analyses by LightCycler in 20 selected C. jejuni strains, 
including EF, for the detection of polymorphism at CdtB-95. A negative control is 
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included. Vertical lines represent the presence of proline (codon - cct) (blue) (as 
represented by strain 81116), serine (codon - tct) (green) (as represented by strains 
EF, S58 and 99/373) or more than one bp mismatch (orange) (as represented by strain 
99/12) at CdtB-95. A no template control (NTC) was used in each run. 
 
FIG. 6. CDT activities of C.jejuni strains 99/68 and EF, complemented with a 2.4 kb 
region from C.jejuni 11168 containing the cdt genes to give 99/68 pCDT and EF 
pCDT, and the same strains in which site directed mutagenesis was performed to 
replace proline at CdtB-95 with serine generating 99/68pCDTP95S and EF pCDTP95S. 
Assays were performed in triplicate and C. jejuni 11168 was used as a positive 
control. 
 
FIG. 7. RT-PCR of total RNA extracted from the caecal contents of chickens 
colonized with C. jejuni strain C289/6 (CDT-positive) and from campylobacter-free 
birds, using primers DS15 and DS18 to detect the expression of cdtA and cdtB. C. 
jejuni 11168 grown in vitro was used as the positive control. Lanes A: reverse 
transcribed RNA sample; lanes B: RT negative controls; lanes C: DNA controls. 
Lanes containing a 1 kb ladder were included (MW).  
 
FIG.  8. Lysates of C. jejuni strains 81116, 81-176 and 11168 were treated with rabbit 
antisera directed against strain 81116 whole cells (R12)        , strain EF (R43)      , 
pooled campylobacteriosis patient sera         , pooled experimentally colonized 
chicken sera (||) prior to CDT activity assays. Sera from pooled normal human blood 
donors        as well as sera from pre-immunized rabbits (§) and uncolonized chickens 
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(data not shown) were used as controls. The lysates were tested for CDT activity and 
the % neutralization determined by comparison with untreated lysates. 
 
FIG. 9. Western blots showing reactivity of sera from human blood donors (A), 
human campylobacterosis patients (B), uncolonized chickens (C) and experimentally 
C. jejuni 81116 colonised chickens (D) to total protein profiles of C. jejuni 11168 and 
81-176. Molecular mass markers are shown on right of figure (MW).   
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FIG. 1. Amplified products of cdtA, B, and C of selected strains, with known in vitro 
CDT activity, using primers cdt-F and cdt-R.  
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FIG. 2. Schematic diagram of the cdtABC of C. jejuni 81-176 illustrating the locations 
of the 667 and 50 bp deletions in strains C37596, C37533 and C35926. Arrows 
indicate direction of transcription  
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FIG. 3. Alignment of the CdtB amino acid sequences of C. jejuni strains EF, 11168 
and other bacterial species. Shaded areas highlight amino acids identical to C. jejuni 
11168. Accession numbers are as follows: C. jejuni EF - AY445094, C. jejuni 11168 
CdtB - CAB72564, C. upsaliensis CdtB - AAF98364, A. actinmyetemcomitians CdtB 
- AAC70898. H. ducreyi CdtB - AAB57726, H. hepaticus CdtB - AAF19158 and E. 
coli CdtB -2010282B. Asterisks indicate point mutations found in C. jejuni EF. The 
amino acids are numbered continuously on the left. 
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FIG. 4. RT-PCR to detect the expression of CDT in C. jejuni EF and 11168, using 
primers DS15 and DS18 to amplify a 450 bp region overlapping cdtA and cdtB (Panel 
A) and strains, 99/373, S58 and 99/12 (Panel B). Lanes A – reverse transcribed RNA 
sample, lanes B- RT negative controls; lanes C, DNA controls. Lanes containing a 1 
kb ladder were included (M).  
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FIG. 5. Melting curve analyses by LightCycler in 20 selected C. jejuni strains, 
including EF, for the detection of polymorphism at CdtB-95. A negative control is 
included. Vertical lines represent the presence of proline (codon - cct) (blue) (as 
represented by strain 81116), serine (codon - tct) (green) (as represented by strains 
EF, S58 and 99/373) or more than one bp mismatch (orange) (as represented by strain 
99/12) at CdtB-95. A no template control (NTC) was used in each run. 
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FIG. 6. CDT activities of C.jejuni strains 99/68 and EF, complemented with a 2.4 kb 
region from C.jejuni 11168 containing the cdt genes to give 99/68 pCDT and EF 
pCDT, and the same strains in which site directed mutagenesis was performed to 
replace proline at CdtB-95 with serine generating 99/68pCDTP95S and EF pCDTP95S. 
Assays were performed in triplicate and C. jejuni 11168 was used as a positive 
control. 
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FIG. 7. RT-PCR of total RNA extracted from the caecal contents of chickens 
colonized with C. jejuni strain C289/6 (CDT-positive) and from campylobacter-free 
birds, using primers DS15 and DS18 to detect the expression of cdtA and cdtB. C. 
jejuni 11168 grown in vitro was used as the positive control. Lanes A: reverse 
transcribed RNA sample; lanes B: RT negative controls; lanes C: DNA controls. 
Lanes containing a 1 kb ladder were included (M).  
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FIG.  8. Lysates of C. jejuni strains 81116, 81-176 and 11168 were treated with rabbit 
antisera directed against strain 81116 whole cells (R12)        , strain EF (R43)      , 
pooled campylobacteriosis patient sera         , pooled experimentally colonized 
chicken sera (||) prior to CDT activity assays. Sera from pooled normal human blood 
donors        as well as sera from pre-immunized rabbits (§) and uncolonized chickens 
(data not shown) were used as controls. The lysates were tested for CDT activity and 
the % neutralization determined by comparison with untreated lysates. 
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FIG.9.  Western blots showing reactivity of sera from human blood donors (A), 
human campylobacterosis patients (B), uncolonized chickens (C) and experimentally 
C. jejuni 81116 colonised chickens (D) to total protein profiles of C. jejuni 11168 and 
81-176. Molecular mass markers are shown on right of figure (M).   
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